Charles River Laboratories (CRL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Charles River Laboratories (CRL) has a cash flow conversion efficiency ratio of 0.014x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($41.08 Million) by net assets ($2.99 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review Charles River Laboratories financial flexibility index to assess the company's free cash flow relative to its total liabilities.
Charles River Laboratories - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Charles River Laboratories's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see CRL company net worth for the company's overall valuation and market capitalisation.
Charles River Laboratories Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Charles River Laboratories ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brixmor Property
NYSE:BRX
|
0.046x |
|
FirstCash Inc
NASDAQ:FCFS
|
0.067x |
|
Enlight Renewable Energy Ltd
TA:ENLT
|
0.041x |
|
Grupo Aeroportuario del Pacífico S.A.B. de C.V
MX:GAPB
|
0.183x |
|
Demant A/S
CO:DEMANT
|
0.238x |
|
ALSTOM S.A. UNSP.ADR 1/10
F:AOMU
|
N/A |
|
Nuvalent Inc
NASDAQ:NUVL
|
-0.079x |
|
SARTORIUS (UNSP.ADS)/1/5
F:SRT0
|
0.049x |
Annual Cash Flow Conversion Efficiency for Charles River Laboratories (1998–2025)
The table below shows the annual cash flow conversion efficiency of Charles River Laboratories from 1998 to 2025. View Charles River Laboratories share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.21 Billion | $737.65 Million | 0.230x | +9.70% |
| 2024-12-31 | $3.51 Billion | $734.58 Million | 0.209x | +12.03% |
| 2023-12-31 | $3.66 Billion | $683.90 Million | 0.187x | -8.80% |
| 2022-12-31 | $3.02 Billion | $619.64 Million | 0.205x | -30.18% |
| 2021-12-31 | $2.59 Billion | $760.80 Million | 0.294x | +15.12% |
| 2020-12-31 | $2.14 Billion | $546.58 Million | 0.255x | -11.65% |
| 2019-12-31 | $1.67 Billion | $480.94 Million | 0.289x | -12.45% |
| 2018-12-31 | $1.34 Billion | $441.14 Million | 0.330x | +10.90% |
| 2017-12-31 | $1.06 Billion | $316.26 Million | 0.297x | -14.93% |
| 2016-12-31 | $853.78 Million | $298.32 Million | 0.349x | -6.59% |
| 2015-12-31 | $765.56 Million | $286.36 Million | 0.374x | +4.94% |
| 2014-12-31 | $704.35 Million | $251.05 Million | 0.356x | +14.37% |
| 2013-12-31 | $664.66 Million | $207.14 Million | 0.312x | -9.58% |
| 2012-12-31 | $603.20 Million | $207.90 Million | 0.345x | -11.16% |
| 2011-12-31 | $529.14 Million | $205.28 Million | 0.388x | +58.09% |
| 2010-12-31 | $688.73 Million | $169.01 Million | 0.245x | +49.81% |
| 2009-12-31 | $1.37 Billion | $225.04 Million | 0.164x | -29.82% |
| 2008-12-31 | $1.20 Billion | $279.95 Million | 0.233x | +53.05% |
| 2007-12-31 | $1.86 Billion | $284.25 Million | 0.152x | +48.85% |
| 2006-12-31 | $1.60 Billion | $164.37 Million | 0.102x | -20.50% |
| 2005-12-31 | $1.84 Billion | $236.70 Million | 0.129x | +3.35% |
| 2004-12-31 | $1.48 Billion | $184.83 Million | 0.125x | -52.17% |
| 2003-12-31 | $474.80 Million | $123.77 Million | 0.261x | -26.68% |
| 2002-12-31 | $375.94 Million | $133.66 Million | 0.356x | +50.84% |
| 2001-12-31 | $302.50 Million | $71.30 Million | 0.236x | -9.08% |
| 2000-12-31 | $130.26 Million | $33.77 Million | 0.259x | +175.79% |
| 1999-12-31 | $-109.84 Million | $37.57 Million | -0.342x | -254.24% |
| 1998-12-31 | $168.56 Million | $37.38 Million | 0.222x | -- |
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in … Read more